Skip to main content

Table 3 Clinical trialsusing Semaphorins as biomarkersfor cancer

From: SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia

ClinicalTrials.gov Identifier

Recruitment status

Endpoints

Cancer histotype

NCT03663153

Not yet recruiting

Semaphorin 4C as a relapse biomarker

Breast cancer

NCT03662633

Not yet recruiting

Semaphorin 4C as diagnostic value

Breast cancer

NCT02747355

Unknown

Semaphorin 3A and Neuropilin1 as proliferation biomarkers

Adreno-cortical tumors

NCT01063387 Phase 1

Unknown

Semaphorin 4C as biomarker of response to therapy

Locally advanced uterine cervical cancer exposed to extended-field irradiation

NCT03517176 Phase 1

Completed

Neuropilin1 as biomarker of response to therapy

Metastatic pancreatic cancer treated with CEND1/Paclitaxel/Gemcitabine

NCT01471470 Phase 2

Completed

Neuropilin1 as angiogenic biomarker

Unresectable advanced gastric cancer treated with Docetaxel, Capecitabine, Cisplatin, and Bevacizumab

NCT02129257 Phase 2

Completed

Semaphorins, Neuropilin1 and 2 as biomarker of response to therapy

Advanced colorectal cancer treated with combination chemotherapy with Aflibercept

NCT01478594 Phase 2

Completed

Neuropilin as biomarker of response to therapy

Metastatic colorectal cancer treated with mFOLFOX6/Tivozanib/ Bevacizumab

NCT04252456 Not Applicable

Recruiting

Neuropilin as angiogenic biomarker

Metastatic colorectal cancer treated with Folfiri/Aflibercept

NCT02854618 Not Applicable

Recruiting

Neuropilin2 asbiomarker of immune response

Metastatic breast cancer treated with Everolimus

NCT01989780 Phase 2

Unknown

Neuropilin as angiogenic biomarker

Breast cancer treated with Bevacizumab/Paclitaxel/ Endocrine therapy